Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
- Author(s)
- Cheasley, D; Llaurado Fernandez, M; Kobel, M; Kim, H; Dawson, A; Hoenisch, J; Bittner, M; Chiu, DS; Talhouk, A; Gilks, CB; Jayawardana, MW; Pishas, KI; Mes-Masson, AM; Provencher, D; Nigam, A; Hacker, NF; Gorringe, KL; Campbell, IG; Carey, MS;
- Journal Title
- NPJ Precision Oncology
- Publication Type
- Research article
- Abstract
- Hormone receptor expression is a characteristic of low-grade serous ovarian carcinoma (LGSOC). Studies investigating estrogen receptor (ER) and progesterone receptor (PR) expression levels suggest its prognostic and predictive significance, although their associations with key molecular aberrations are not well understood. As such, we sought to describe the specific genomic profiles associated with different ER/PR expression patterns and survival outcomes in a cohort of patients with advanced disease. The study comprised fifty-five advanced-staged (III/IV) LGSOCs from the Canadian Ovarian Experimental Unified Resource (COEUR) for which targeted mutation sequencing, copy-number aberration, clinical and follow-up data were available. ER, PR, and p16 expression were assessed by immunohistochemistry. Tumors were divided into low and high ER/PR expression groups based on Allred scoring. Copy number analysis revealed that PR-low tumors (Allred score <2) had a higher fraction of the genome altered by copy number changes compared to PR-high tumors (p = 0.001), with cancer genes affected within specific loci linked to altered peptidyl-tyrosine kinase, MAP-kinase, and PI3-kinase signaling. Cox regression analysis showed that ER-high (p = 0.02), PR-high (p = 0.03), stage III disease (p = 0.02), low residual disease burden (p = 0.01) and normal p16 expression (p<0.001) were all significantly associated with improved overall survival. This study provides evidence that genomic aberrations are linked to ER/PR expression in primary LGSOC.
- Department(s)
- Laboratory Research; Office of Cancer Research
- PubMed ID
- 35768582
- Publisher's Version
- https://doi.org/10.1038/s41698-022-00288-2
- Open Access at Publisher's Site
https://doi.org/10.1038/s41698-022-00288-2- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-16 03:58:17
Last Modified: 2024-10-16 03:59:23